Event Description
Topic
Inhibition of Parkinson’s Protein Leucine-Rich Repeat Kinase 2 (LRRK2) by an FDA-approved Compound
Presented By
Iban Ubarretxena-Belandia, PhD, associate professor of pharmacological sciences; co-director, PhD Program in Biophysics & Systems Pharmacology, Icahn School of Medicine at Mount Sinai
Hosted By
Shae Padrick, PhD, assistant professor, Biochemistry and Molecular Biology |